Gilead Sciences (GILD) and Merck (MRK) announced new results from a Phase 2 clinical study evaluating the investigational ...

Gilead Sciences Inc. (GILD) and Merck & Co Inc.(MRK) announced new results from a Phase 2 clinical study evaluating the ...

Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today ...

Lenacapavir/islatravir combo carries mechanistic rationale Mixed oral/subQ regimens don’t provide additional convenience ...

Merck & Co has halted enrolment in a pair of phase 3 trials of its experimental HIV drug islatravir, raising another warning flag about the highly-touted therapy. The two studies – IMPOWER 22 ...

One patient on islatravir/lenacapavir did show a detectable viral load of more than 50 copies/mL at 24 weeks, but fell below that threshold at 30 weeks, according to Gilead and MSD, and two ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research ...

New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and ...

Injectable Drug Market. The global injectable drug market is poised for significant growth, with an estimated valuation of ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial ...

The role of chancellor at the University of Oxford has been around for 800 years. This year, a particularly broad range of people have applied. By Mark Landler Before Hamas’s Oct. 7 attacks ...

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new findings from its antiviral research and development programs at IDWeek ...